Drug name
Last update: Jul 2026VH-184 (VH-4524184)
Developer(s)
Drug information
Not provided
VH-4524184 ; VH-184
investigational
Small molecule
Integrase strand transfer inhibitor (INSTI)
VH4524184 (VH-184) is an investigational third-generation integrase strand transfer inhibitor (INSTI) with long-acting potential, similar to dolutegravir, with a higher barrier to resistance. INSTIs exert their antiviral effect by targeting the HIV integrase enzyme, thereby inhibiting viral replication. There is an emerging resistance trend to some 2nd generation INSTIs. Preclinical in vitro studies indicate that VH-184 demonstrates antiviral potency comparable to 2nd generation INSTIs dolutegravir and cabotegravir, with a protein-adjusted 90% effective concentration (EC90) of 160 nM and an improved resistance profile. VH-184 is being pursued as injectable for subcutaneous or intramuscular administration, as a backbone for future HIV treatment regimens.
VH4524184 (VH-184) is currently in clinical development and not yet approved in any jurisdiction. Two injectable LA formulations are evaluated. Formulation A showed a median Cmax at Day 3 and a terminal half-life of ~7 weeks, supporting Q1M/Q2M dosing. Formulation B demonstrated slower absorption with flat PK through Month 7; terminal half-life was not estimable, supporting Q6M dosing. ISRs were predominantly Grade 1–2; two Grade 3 events were reported. The VH-184 demonstrated enhanced potency versus bictegravir across key resistance mutations, retaining wild-type–level activity
VH4524184 (VH-184) is currently in clinical development and not yet approved in any jurisdiction.
Therapeutic area(s)
- HIV
- Treatment
Administration route
Oral, , Subcutaneous, Intramuscular
Associated long-acting platforms
unknown
Use of drug
- To be determined
- Administered by a nurse
- Administered by a specialty health worker
- Administered by a community health worker
- Self-administered
- Monthly
- Every 2 months
- Every 6 weeks
- Every 4 months
Dosage
Formulation A: [240mg (0.8 mL), 420 mg (1.4mL); 750 mg (2.5 mL)] SC and [450mg (1.5 mL), 900 mg (3 mL)] IM. Formulation B: [400 mg (1 mL); 800mg (2 mL) IM and SC]
900 mg (3mL) IM into the thigh muscle
A Phase 2a, oral, proof‑of‑concept study in antiretroviral‑therapy (ART)–naïve people with HIV (PWH) (NCT06214052) evaluated VH‑184 administered at doses of 10 mg, 50 mg, and 300 mg every three days. Long‑acting formulations of VH‑184, including both intramuscular (IM) and subcutaneous (SC) depot preparations, are currently under evaluation in a separate clinical study (NCT06310551). Population pharmacokinetic analyses indicate that the long‑acting formulation A may be suitable for monthly or every‑two‑month administration, whereas the formulation B may enable dosing at four month and six‑month intervals.
Not provided
Not provided
Associated compounds, formulations and regimens
Not provided
Associated technologies
Not provided
Additional information
Developer(s)
ViiV Healthcare
ViiV Healthcare is a pharmaceutical company that specializes in the development of therapies for HIV infection. The company is headquartered in Brentford in the United Kingdom and was initially formed in November 2009 as a part of a joint venture between GlaxoSmithKline and Shanogi.
Shionogi
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919.
Drug structure
Scale-up and manufacturing prospects
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Detailed manufacturing information is not currently available for this compound.
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Not provided
Not provided
Not provided
Not provided
VH184 compound markush structure
A compound represented in formula (I) is provided. (In the formula, ring A is a substituted or unsubstituted non-aromatic heterocycle; ring C is a benzene ring, etc.; Q is a 5-membered aromatic heterocycle, etc.; the R1s are independently a halogen, etc.; L is a substituted or unsubstituted alkylene; R3 is a substituted or unsubstituted alkyl, etc.; R4 is a hydrogen, etc.; and n is an integer 1 to 3.)
WO2019230857
Compound
SHIONOGI & CO., LTD.
Not provided
May 30, 2039
Granted: AU, CL, CN, EAPO (AM, AZ, BY, KG, KZ, RU, TJ, TM), IL, IN, JP, KR, MX, MY, US Pending: BR, CA, CR, CO, DO, DZ, EG, EPO, ID, NG, PE, PH, SG, TH, TT, UA, VN, ZA
VH184 compound markush structure
A compound represented in formula (I) is provided. (In the formula, ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring, etc.; R1 is a halogen, etc.; R2a and R2b are independently a hydrogen, etc.; R3 is a substituted or unsubstituted alkyl, etc.; R4 is a hydrogen, etc.; and n is an integer 1 to 3.)
WO2019230858
Compound
SHIONOGI & CO., LTD.
Not provided
May 30, 2039
Granted: AU, BR, CN, EA (AM, AZ, BY, KG, KZ, RU, TJ, TM), EP (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, BA, ME), KR, IN, JP, MY, US, ZA Pending: AR, CA, CL, CO, CR, DO, DZ, EG, HK, ID, MX, NZ, PE, PH, SG, TH, TT, TW, UA, VN Not in force: KH, MA, MD, TN